Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000059331) titled 'Special drug use-results survey on BALVERSA' on Oct. 8.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: Janssen Pharmaceutical K.K.
Condition:
unresectable urothelial carcinoma with FGFR3 gene mutations or fusion genes that has progressed after cancer chemotherapy
Recruitment Status: Not Recruiting
Phase: Not selected
Date of First Enrollment: 2025/11/01
Target Sample Size: 58
Countries of Recruitment:
Japan
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066915
Published by HT Digital Content Services with permission ...